-0.82 (-4.48%)
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
First Tracks Biotherapeutics, a clinical-stage biotech firm, announced its participation in several upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum. CEO Daniel Faga and other executives will represent the company. A live webcast of the presentations will be available, with replays accessible for 30 days.
Read more →First Tracks Biotherapeutics, a clinical-stage biotechnology firm, announced its participation in several upcoming investor conferences. CEO Daniel Faga and other executives will present at the 2026 Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum. The company focuses on developing antibody therapies for autoimmune and inflammatory diseases.
Read more →First Tracks Biotherapeutics, Inc., reported its financial results for the first quarter of 2026, highlighting a significant launch with $180 million in cash. The company aims to advance its lead candidate ANB033 through ongoing Phase 1b trials in celiac disease and eosinophilic esophagitis. It also received positive feedback from the FDA regarding the development pathway for rosnilimab in rheumatoid arthritis. However, the company recorded a net loss of $50.5 million, reflecting increased general administrative costs associated with its recent separation from AnaptysBio.
Read more →First Tracks Biotherapeutics has officially debuted on Nasdaq under the ticker symbol TRAX, launching as a clinical-stage biotech company focused on developing antibody therapeutics for autoimmune diseases. The company has announced a robust cash reserve of $180 million, which supports its initial programs, including ANB033 for celiac disease. Trading begins today, marking the company's emergence after distribution to AnaptysBio shareholders. First Tracks aims to make meaningful advancements in managing immune pathway-related diseases.
Read more →AnaptysBio, Inc. has announced plans to separate its biopharma operations from its royalty assets, creating two publicly traded companies. The newly formed First Tracks Biotherapeutics, Inc. (TRAX) will handle the biopharma segment and is set to distribute shares to Anaptys shareholders in a tax-free spin-off. The distribution is scheduled for April 20, 2026, and existing shareholders will receive shares on a one-for-one basis for each share of Anaptys they hold. The spin-off aims to provide a focused operational strategy and is anticipated to attract investor interest.
Read more →